BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc.（BTAI）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
btai · 股价预测 · 15 位分析师（近3月）· FMP · 更新于 2026年6月9日
分析师评级与共识
基于过去 3 个月内 15 位华尔街分析师
Buy
15 位分析师
共识
评级分布
12 个月目标价
High
$25.00
Consensus
$12.00
+986.0% upside
Low
$1.00
Median: $10 · Last Close: $1.10
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$12.00
986.0% upside
High Target
$25
2162.4%
Low Target
$1
-9.5%
Current Price
$1.10
as of today
Based on analyst price targets, the BTAI stock price prediction for the next 12 months ranges from $1 to $25. The consensus BTAI price forecast of $12.00 implies 986.0% upside from the current price of $1.10.
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.10 | ↓ 0.66% |
1-day model range: $1.07–$1.12. Peak: $1.12 (-0.66%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · BTAI · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-12 | Mizuho | Maintains | Neutral→Neutral |
| 2025-08-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-07-15 | LUCID CAPITAL MARKETS | Maintains | Buy→Buy |
| 2025-06-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on BioXcel Therapeutics, Inc. (BTAI) stock. Of the recent 97 rating actions, 1 were upgrades and 7 were downgrades. 15 analysts currently cover BTAI.
分析师推荐趋势
BTAI analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$2M
↓ 97.4% YoY
Revenue Next Year
$19M
↑ 1043.3% YoY
EPS This Year
$-1.67
EPS Next Year
$-1.53
↓ 8.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast BTAI EPS of $-1.67 for the current fiscal year, based on estimates from 1 analysts. The BTAI revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
BTAI 股价预测由两类独立数据源支撑：来自 15 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。BTAI 的共识目标价为 $12.00（+986.0% 上行空间），分析师共识为 Buy。
BTAI 的短期预测（明日）为 $1.10（-0.66%）。
BioXcel Therapeutics, Inc. 在 NASDAQ 上市，代码 BTAI。BTAI 在 2027 年的整体展望偏积极，在覆盖分析师中约 53% 对应 Buy 共识。
常见问题
BTAI 预测 · 8 个问题根据 15 位华尔街分析师，BTAI 的 12 个月平均目标价为 $12.00，最高 $25.00、最低 $1.00。若有图表，中位目标价可在上方查看。相对当前价 $1.10，隐含约 +986.0% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.